Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences
May 25 2021 - 7:30AM
Business Wire
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
biotechnology company focused on harnessing the body’s innate
biology to repair or reverse damage caused by a broad range of
degenerative diseases, today announced that Chief Executive Officer
David L. Lucchino will present at two upcoming investor
conferences:
- Jefferies Virtual Healthcare Conference on June 2, 2021 at 2:30
p.m. EDT
- Goldman Sachs 42nd Annual Global Healthcare Conference on June
10, 2021 at 8:00 a.m. EDT
A live webcast of the presentations can be accessed on the
investors section of Frequency’s website,
investors.frequencytx.com. A replay of the presentations will be
posted on the Frequency website following the event.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of
medicines designed to activate progenitor cells within the body to
treat degenerative diseases. The Company’s progenitor cell
activation (PCA) approach stimulates progenitor cells to create
functional tissue with the aim of developing disease modifying
therapies. The Company’s lead product candidate, FX-322, is
designed to regenerate auditory hair cells to restore hearing
function. FX-322 is being evaluated in multiple ongoing clinical
studies in patients with sensorineural hearing loss. The Company
also is evaluating additional diseases where its PCA approach could
create functional tissue, including in a pre-clinical program in
multiple sclerosis.
Headquartered in Lexington, Mass., Frequency has an ex-U.S.
license and collaboration agreement with Astellas Pharma Inc. for
FX-322, as well as additional collaboration and licensing
agreements with academic and nonprofit research organizations
including Massachusetts Eye and Ear, Mass General Brigham,
Massachusetts Institute of Technology, The Scripps Research
Institute and Cambridge Enterprises Limited. For more information,
visit www.frequencytx.com and follow Frequency on Twitter
@Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210525005105/en/
Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor Relations
ctanzi@kendallir.com 617-914-0008
Media Contact: Suzanne Day Frequency Therapeutics
sday@frequencytx.com 781-496-2211
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Sep 2023 to Sep 2024